Intrinsic Expression of the Multidrug Transporter, P-Glycoprotein 170, in Multiple Myeloma: Implications for Treatment

References

• Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasmacell myeloma-new biological insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Ralph Q. M., Brisco M. J., Joshua D. E., Brown R., Gibson J., Morley A. A. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: Evidence from the Ig heavy chain gene. Blood 1993; 82: 202–206
   PubMed Web of Science ®Google Scholar
• Higgins C. F. ABC transporters: from microrganisms to man. Ann. Rev. Cell. Biol. 1992; 8: 67–113
   PubMedGoogle Scholar
• Gill D. R., Hyde S. C., Higgins C. F., Valverde M. A., Mintenig G. M., Sepulveda F. V. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 1992; 71: 23–32
   PubMed Web of Science ®Google Scholar
• Gros P., Croop J., Housman D. Mammaliam multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986; 47: 371–380
   PubMed Web of Science ®Google Scholar
• Chen C.-J., Chin J. E., Ueda K., Clark D. P., Pastan I., Gottesman M., Roninson I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381–389
   PubMed Web of Science ®Google Scholar
• Raymond M., Gros P., Whiteway M., Thomas D. Y. Functional complementation of yeast ste6 by a mammalian multidrug resistance mdr gene. Science 1992; 256: 232–234
   PubMed Web of Science ®Google Scholar
• Hyde S. C., Emsley P., Hartshorn M. J., Mimmack M. M., Gileadi U., Pearce S. R., Gallagher M. P., Gill D. R., Hubbard R. E., Higgins C. F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990; 346: 362–365
   PubMed Web of Science ®Google Scholar
• Monaco J. J., Cho S., Attaya M. Transport protein genes in the murine MHC: possible implications for antigen processing. Science 1990; 250: 1723–1726
   PubMed Web of Science ®Google Scholar
• Spies T., Bresnahan M., Bahram S., Arnold D., Blanck G., Mellins E., Pious D., De Mars R. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990; 348: 744–747
   PubMed Web of Science ®Google Scholar
• Kelly A., Powis S. H., Kerr L., Mockridge I., Elliott T., Bastin J., Uchanska-Ziegler B., Ziegler A., Trowsdale J., Townsend A. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 1992; 355: 641–644
   PubMed Web of Science ®Google Scholar
• Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS 1993; 324: 99–102
   PubMed Web of Science ®Google Scholar
• Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human p-glycoprotein transports cyclosporin A and FK506. J. Biol. Client. 1993; 268: 6011–6080
   Google Scholar
• Arceci R. J., Stieglitz K., Bierer B. E. Immunosuppressants FK506 and rapamycine function as reversal agents of the multidrug resistance phenotype. Blood 1992; 80: 1528–1536
   PubMed Web of Science ®Google Scholar
• Naito M., Oh-Hara T., Yamazaki Y., Danki T., Tsuruo T. Reversal of multidrug resistance by an immunospuuressive agent FK-506. Cancer Chemother. Pharmacol. 1992; 29: 195–200
   PubMed Web of Science ®Google Scholar
• Lelong I. H., Guzikowski A. P., Haugland R. P., Pastan I., Gottesman M. M., Willingham M. C. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter. Molec. Pharmacol. 1991; 40: 490–494
   PubMed Web of Science ®Google Scholar
• Higgins C. F., Gottesman M. M. Is the multidrug transporter a flippase?. TIBS 1992; 17: 18–21
   PubMed Web of Science ®Google Scholar
• Tatsuta T., Naito M., Oh-Hara T., Sugawara I., Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol. Chem. 1992; 267: 20383–20391
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., O'Brien J. P., Casals D., Rittman-Grauer L., Biedler J. L., Melamed M. R., Bertino J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sides. Proc Natl Acad. Sci. USA 1989; 86: 695–698
   PubMed Web of Science ®Google Scholar
• Tsuji A., Tamai I., Sakata A., Tenda Y., Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 1993; 46: 1096–1099
   PubMed Web of Science ®Google Scholar
• Ito S., Woodland C., Harper P. A., Koren G. P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. Life Sci. 1993; 53: 25–31
   Google Scholar
• Thiebaut F., Tsuro T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues. Proc. Nat. Acad. Sci. USA 1987; 84: 7735–7738
   PubMed Web of Science ®Google Scholar
• Gupta S., Kim C. H., Tsuruo T., Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-Glycoprotein), a functionally active efflux pump, in human CD8 + T cells: a role in cytotoxic effector function. J. Clin. Immunol. 1992; 12: 451–458
   PubMed Web of Science ®Google Scholar
• Gupta S., Gollapudi S. P-glycoprotein (MDR I gene product) in cells of the immune system: Its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-I) infection. J. Clin. Immunol. 1993; 13: 289–301
   PubMed Web of Science ®Google Scholar
• Chaudhary P. M., Mechetner E. B., Roninson I. B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735–2739
   PubMed Web of Science ®Google Scholar
• Klimecki W. T., Futscher B. W., Grogan T. M., Dalton W. S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451–2458
   PubMed Web of Science ®Google Scholar
• Valverde M. A., Diaz M., Sepulveda F. V., Gill D. R., Hyde S. C., Higgins C. F. Volume-regulated chlorine channels associated with the human multidrug-resistance p-glycoprotein. Nature 1992; 355: 830–833
   PubMed Web of Science ®Google Scholar
• Abraham E. H., Prat A. G., Gerweck L., Seneveratne T., Arceci R. J., Kramer R., Guidotti G., Cantiello H. F. The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc. Nat. Acad. Sci. USA 1993; 90: 312–316
   PubMed Web of Science ®Google Scholar
• Sarkadi B., Price E. M., Boucher R. C., Germann U. A., Scarborough G. A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 1992; 267: 4854–4858
   PubMed Web of Science ®Google Scholar
• Scharma R. C., Inoue S., Roitelman J., Schimke R. T., Simoni R. D. Peptide transport by the multidrug resistance pump. J. Biol. Chem. 1992; 267: 5731–5734
   PubMed Web of Science ®Google Scholar
• Kohno K., Sato S.-I., Takano H., Matuso K-I, Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem. Biophys. Res. Comm. 1989; 165: 1415–1421
   PubMed Web of Science ®Google Scholar
• Hynes R. O. Integrins: Versitility modulation and signalling in cell adhesion. Cell 1992; 69: 11–25
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Belch A. R. Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 1994; 83: 724–736
   PubMed Web of Science ®Google Scholar
• Bergsagel D. E. Treatment of plasma cell myeloma. Ann. Rev. Med 1979; 30: 431–433
   PubMed Web of Science ®Google Scholar
• Palmer M., Belch A., Hanson J., Brox L. Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. Br. J. Cancer 1989; 59: 110–112
   PubMed Web of Science ®Google Scholar
• Belch A., Shelley W., Bergsagel D., Wilson K., Klimo P., Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding myeloma patients. Br. J. Cancer 1988; 57: 94–99
   PubMed Web of Science ®Google Scholar
• Greipp P. R. Advances in the diagnosis and management of myeloma. Sem. Hematol. 1992; 29: 24–45
   PubMed Web of Science ®Google Scholar
• Barlogie B., Gahrton G. Bone arrow transplantation in multiple myeloma. Bone Marrow Transplant. 1991; 7: 71–79
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Milpiel N., Laporte J. P., Collombat P., Facon T., Tigaud J. D., Casassus P., Guilhot F., Ifrah N., Gandhour C. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 2827–2833
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Durie B. G. M., Lokhorst H. M., Marie J.-P., Solbu G., Suciu S., Zittroun R., Lowenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992; 340: 255–259
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Dalton W. S., Grogan T. M., Plezia P., Lehnert M., Roe D. J., Miller T. P. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44–50
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Grogan T. M., Meltzer P. S., Scheper R. J., Durie B. G. M., Taylor C. W., Miller T. P., Salmon S. E. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 1989; 7: 415–424
   PubMed Web of Science ®Google Scholar
• Durie B. G. M., Dalton W. S. Reversal of drug-resistance in multiple myeloma with verapamil. British Journal of Haematology 1988; 68: 203–206
   PubMed Web of Science ®Google Scholar
• Carulli G., Petrini M., Marini A., Ambrogi F., Ucci G., Riccardi A., Luoni R., Grassi B. P-glycoprotein expression in multiple myeloma. Haematologica 1990; 75: 288–290
   PubMedGoogle Scholar
• Pilarski L. M., Jensen G. S. Monoclonal circulating B cells in multiple myeloma: A continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematology/Oncology Clinics of North America 1992; 6: 297–322
   PubMed Web of Science ®Google Scholar
• Jensen G. S., Belch A. R., Kherani F., Mant M. J., Ruether B. A., Pilarski L. M. Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CDI lb on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scand. J. Immunol. 1992; 36: 843–853
   PubMed Web of Science ®Google Scholar
• Jensen G. S., Belch A. R., Mant M. J., Ruether B. A., Yacyshyn B. R., Pilarski L. M. Expression of multiple beta-1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am. J. Hematol 1992; 43: 29–36
   Web of Science ®Google Scholar
• Jensen G. S., Mant M. J., Belch A. J., Berensen J. R., Ruether B. A., Pilarski L. M. Selective expression of CD45 isoforms defines CALLA+ monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991; 78: 711–719
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Masellis Smith A., Belch A. R., Yang B., Savani R. C., Turley E. A. RHAMM, a receptor for hyaluronan-mediated molility, on normal lymphocytes, thymocytes and in B cell malignancy: A mediator of B cell malignancy?. Leuk. Lymphoma 1994, in press
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Mant M. M., Belch A. R. Circulating, monoclonal, multi-drug resistant B cells may comprise the malignant stem cells population in multiple myeloma.: in Challenges of Modem Medicine, F. Dammaco, B. Barlogie. Area Sereno Press. 1994; 4: 31–49
   Google Scholar
• Billadeau D., Quam L., Thomas W., Kay M., Greipp P., Kyle R., Oken M. M., Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818–1824
   PubMed Web of Science ®Google Scholar
• Corradini P., Voena C., Omede P., Astolfi M., Boccadoro M., Dalla-Favera R., Pilieri A. Detection of circulating tumor cells in multiple myeloma by a PCR based method. Leukemia 1993; 7: 1879–1882
   PubMed Web of Science ®Google Scholar
• Dreyfus F., Melle J., Quarre C., Pillier C. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high dose chemotherapy. Brit. J. Hematol. 1993; 85: 411–412
   PubMed Web of Science ®Google Scholar
• Bergsagel P. L., Masellis-Smith A., Belch A. R., Pilarski L. M. The blood B cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Current Topics in Microbiol, and Immunol. 1994, in press
   Google Scholar
• Baumhueter S., Singer M. S., Henzel W., Hemmerich S., Renz M., Rosen S. D., Lasky L. A. Binding of L-selectin to the vascular sialomucin CD34. Science 1993; 262: 436–438
   PubMed Web of Science ®Google Scholar
• Simmons D. L., Satterthwaite A. B., Tenen D. G., Seed B. Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J. Immunol. 1992; 148: 267–271
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Cass C. E., Tsuruo T., Belch A. R. Multidrug resistance of a continuously differentiating monoclonal B lineage in the blood and bone marrow of patients with multiple myeloma. Current Topics In Microbiol. Immunol. 1992; 182: 177–185
   PubMedGoogle Scholar
• Georges E., Tsuruo T., Ling V. Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody. J. Biol. Chem. 1993; 268: 1792–1798
   PubMed Web of Science ®Google Scholar
• Sugawara I., Kodo H., Ohkochi E., Hamada H., Tsuruo T., Mori S. High level expression of MRK 16 and MRK 20 murine monoclonal antibody-defined proteins (170, 000–180, 000 P-glycoprotein and 85, 000 protein) in leukaemias and malignant lymphomas. Brit. J. Cancer 1989; 60: 538–541
   PubMed Web of Science ®Google Scholar
• Ueda K., Okamura N., Hirai M., Tanigawra Y., Saeki T., Kioka N., Komano T., Hori R. Human P-glycoprotein transports Cortisol, aldosterone and dexamethasone but not progesterone. J. Biol. Chem. 1992; 267: 24248–24252
   PubMed Web of Science ®Google Scholar
• Goldie J. H., Ling V. The evolution of drug resistance in tumors. Canad. J. Oncol. 1991; 1: 1–10
   Google Scholar
• Bell D. R., Gerlach J. H., Kartner N., Buick R. N., Ling V. Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance. J. Clin. Oncol. 1985; 3: 311–315
   PubMed Web of Science ®Google Scholar
• Colotta F., Polentarutti N., Sironi M., Mantovan A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J. Biol. Chem. 1992; 267: 18278–18283
   PubMed Web of Science ®Google Scholar
• van Kalkan C. K., Broxterman H. J., Pinedo H. M., Feller N., Dekker H., Lankelma J., Giaccone G. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br. J. Cancer 1993; 67: 284–289
   PubMed Web of Science ®Google Scholar
• Fardel O., Lecureur V., Guillouzo A. Regulation be dexamethasone of p-glycoprotein expression in cultured rat hepatocytes. FEBS 1993; 327: 189–193
   PubMed Web of Science ®Google Scholar
• Hamada H., Hagiwara K. I., Nakajima T., Tsuruo T. Phosphorylation of the M. 170, 000 to 180, 000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 1987; 47: 2860–2865
   PubMed Web of Science ®Google Scholar
• Bell J. B. G., Millar B. C., Maitland J. A., Nandi A., Gore M., McElwain T. J. Increase in clonogenic tumor cells in bone marrow of patients with multiple myeloma treated with vincristine, doxrubicin and methylprednisolone. Lancet 1988; 2: 931–933
   PubMed Web of Science ®Google Scholar
• Anderson K. C., Barut B. A., Ritz J., Freedman A. S., Takvorian T., Rabinowe S. N., Soiffer R., Heflin L., Coral F., Dear K., Mauch P., Nadler L. M. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 1991; 77: 712–720
   PubMed Web of Science ®Google Scholar
• Chaudhary P. M., Roninson I. B. Expression and activity of p-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94
   PubMed Web of Science ®Google Scholar
• Snoeck H-W., Lardon F., Lenjou M., Nys G., Bockstaele D. R., Petermans M. E. Differential regulation of the expression of CD38 and human leukocyte antigen-DR on CD34+ hematopoietic progenitor cells by interleukin-4 and interferon gamma. Exp. Hematol. 1993; 21: 1480–1486
   PubMed Web of Science ®Google Scholar